DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp.

Download PDF:

CUPERTINO, Calif., Oct. 19 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that Voyager Pharmaceutical has informed DURECT
that Voyager is ending its Phase III clinical trials for Memryte(TM) for the
treatment of Alzheimer’s Disease in order to get an earlier look at potential
efficacy from over 600 accrued patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

“We look forward to this early read out of these clinical trials as
Voyager Pharmaceutical continues their efforts to bring these on-going studies
to closure,” stated Dr. James E. Brown, President and CEO for DURECT.

Memryte utilizes DURECT’s proprietary DURIN technology to provide
sustained release of the peptide leuprolide acetate and is based on Voyager’s
patented method of treatment of Alzheimer’s disease. Our DURIN biodegradable
implant technology is a platform for parenteral delivery of drugs for periods
of weeks to six months or more. The technology is based on the use of
biodegradable polymer excipients, which have a proven record of safety in
approved drug delivery and medical device products.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic debilitating diseases and
enable biotechnology products. Additional information about DURECT is
available at www.www.durect.com.

DURECT Forward-Looking Statement

The statements in this press release regarding DURECT’s anticipated growth
and development and Voyager’s development and clinical trial plans are
forward-looking statements including risks and uncertainties that can cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not limited
to, the ability of DURECT and its collaborators including Voyager to
successfully design, enroll, conduct and complete clinical trials, complete
the design, development, and manufacturing process development of the product
candidate, obtain product and manufacturing approvals from regulatory agencies
and manufacture and commercialize the product candidate, as well as
marketplace acceptance of the product candidate. Further information
regarding these and other risks is included in DURECT’s Quarterly Report on
Form 10-Q filed with the SEC on August 9, 2006 under the heading “Risk

CONTACT: Schond L. Greenway, Vice President, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.www.durect.com

Scroll to Top